Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

Gómez‐Ramírez, Susana; Brilli, Elisa; Tarantino, Germano; Múñoz, Manuel

doi:10.3390/ph11040097

Cited by 91 publications

(114 citation statements)

References 80 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Our cost minimization analysis is based on the main clinical trial result, that is the demonstrated same efficacy of oral iron and IV iron. Sucrosomial iron has demonstrated a similar effectiveness, with lower costs, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery) in several studies published recently [25][26][27][28]. In particular, Darbà et al [26] conducted a budget impact analysis of an oral sucrosomial iron in the treatment of patients similar with those of our study.…”

Section: Discussionsupporting

confidence: 82%

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Riccio

Sabbatini²,

Capuano³

et al. 2020

BMC Nephrol

View full text Add to dashboard Cite

Background: Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective. Methods: Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results. Results: The base case analysis showed an average cost/cycle per patient of € 111 for oral iron and € 1302 for IV iron. Thus, the potential saving was equal to € 1191 per patient/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre. Discussion: This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.

show abstract

Section: Discussionsupporting

confidence: 82%

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Riccio

Sabbatini²,

Capuano³

et al. 2020

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…(Supplementary Table S1). This result is consistent with previous studies indicating low toxicity SFP [24,53,54].…”

Section: The Effect Of Oral Iron Supplementation On Placental Morpholsupporting

confidence: 94%

“…( Supplementary Figure 1). This result is consistent with previous studies indicating low toxicity SFP [24,53,54]. To check the potential effect of SFP on the integrity and morphology of placenta we performed an exhaustive analysis of placenta using scanning electron microscopy at different scanning resolutions.…”

Section: The Effect Of Oral Iron Supplementation On Placental Morpholsupporting

confidence: 90%

Effect of Oral Supplementation of Healthy Pregnant Sows with Sucrosomial Ferric Pyrophosphate on Maternal Iron Status and Hepatic Iron Stores in Newborn Piglets

Mazgaj

Szudzik

Lipiński

et al. 2020

Animals

View full text Add to dashboard Cite

Background: The similarities between swine and humans in physiological and genomic patterns, as well as significant correlation in size and anatomy, make pigs an useful animal model in nutritional studies during pregnancy. In humans and pigs iron needs exponentially increase during the last trimester of pregnancy, mainly due to increased red blood cell mass. Insufficient iron supply during gestation may be responsible for the occurrence of maternal iron deficiency anemia and decreased iron status in neonates. On the other hand, preventive iron supplementation of non-anemic mothers may be of potential risk due to iron toxicity. Several different regimens of iron supplementation have been applied during pregnancy. The majority of oral iron supplementations routinely applied to pregnant sows provide inorganic, non-heme iron compounds, which exhibit low bioavailability and intestinal side effects. The aim of this study was to check, using pig as an animal model, the effect of sucrosomial ferric pyrophosphate (SFP), a new non-heme iron formulation on maternal and neonate iron and hematological status, placental transport and pregnancy outcome; Methods: Fifteen non-anemic pregnant sows were recruited to the experiment at day 80 of pregnancy and randomized into the non-supplemented group (control; n = 5) and two groups receiving oral iron supplementation—sows given sucrosomial ferric pyrophosphate, 60 mg Fe/day (SFP; n = 5) (SiderAL®, Pisa, Italy) and sows given ferrous sulfate 60 mg Fe/day (Gambit, Kutno, Poland) (FeSO4; n = 5) up to delivery (around day 117). Biological samples were collected from maternal and piglet blood, placenta and piglet tissues. In addition, data on pregnancy outcome were recorded.; Results: Results of our study show that both iron supplements do not alter neither systemic iron homeostasis in pregnant sows nor their hematological status at the end of pregnancy. Moreover, we did not detect any changes of iron content in the milk and colostrum of iron supplemented sows in comparison to controls. Neonatal iron status of piglets from iron supplemented sows was not improved compared with the progeny of control females. No statistically significant differences were found in average piglets weight and number of piglets per litter between animals from experimental groups. The placental expression of iron transporters varied depending on the iron supplement.

show abstract

“…However, the estimated absorption rate of ferrous salts is 10-15% [33]. Sucrosomial ® iron, a newer iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer and sucrosome, has been shown to be better tolerated than oral iron salts and has demonstrated high iron bioavailability [34]. Korcock et al (2018) [23] reported using Sucrosomial ® iron and was the only study that found an increase in serum iron between the probiotic and control groups.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis on the Effects of Probiotic Species on Iron Absorption and Iron Status

et al. 2019

View full text Add to dashboard Cite

Background: Strategies to prevent iron deficiency anemia (IDA) have varying effectiveness. The purpose of this systematic review of the literature and meta-analysis was to examine the effects of probiotics on iron absorption and iron status-related markers in humans. Methods: We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) reporting guidelines. Relevant articles were identified from Embase, Pubmed, Scopus, and CINAHL from inception to February, 2019. We conducted a meta-analysis for eight studies examining the effect of the probiotic Lactobacillus plantarum 299v (Lp299v) on iron absorption. Results: Fifteen studies reported in 12 articles were identified (N = 950). Our meta-analysis of eight studies using a random-effects model demonstrated a significant increase in iron absorption following administration of the probiotic Lp299v with a pooled standardized mean difference (an average intervention effect size) of 0.55 (95% CI 0.22–0.88, p = 0.001). Of the seven randomized clinical trials (RCTs) and nonrandomized clinical trials examining a range of probiotic species on iron status, only one study supplementing with Lp299v showed improvement in serum iron; no other studies reported improvement in iron status-related indices with probiotic treatment. Conclusions: Lp299v significantly improved iron absorption in humans. Future research should include the assessment of Lp299v effect on iron absorption and iron status in populations at high risk of IDA, including pregnant women.

show abstract

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

Cited by 91 publications

References 80 publications

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Effect of Oral Supplementation of Healthy Pregnant Sows with Sucrosomial Ferric Pyrophosphate on Maternal Iron Status and Hepatic Iron Stores in Newborn Piglets

A Systematic Review and Meta-Analysis on the Effects of Probiotic Species on Iron Absorption and Iron Status

Contact Info

Product

Resources

About